Validation of a SARS-CoV-2 spike ELISA for use in contact investigations and serosurveillance
Freeman, B.; Lester, S.; Mills, L.; Rasheed, M. A. U.; Moye, S.; Abiona, O.; Hutchinson, G.; Morales-Betoulle, M.; Krapinunaya, I.; Gibbons, A.; Chiang, C.-F.; Cannon, D.; Klena, J.; Johnson, J. A.; Owen, S. M.; Graham, B. S.; Corbett, K. S.; Thornburg, N. J.
Show abstract
Since emergence of SARS-CoV-2 in late 2019, there has been a critical need to understand prevalence, transmission patterns, to calculate the burden of disease and case fatality rates. Molecular diagnostics, the gold standard for identifying viremic cases, are not ideal for determining true case counts and rates of asymptomatic infection. Serological detection of SARS-CoV-2 specific antibodies can contribute to filling these knowledge gaps. In this study, we describe optimization and validation of a SARS-CoV-2-specific-enzyme linked immunosorbent assay (ELISA) using the prefusion-stabilized form of the spike protein [1]. We performed receiver operator characteristic (ROC) analyses to define the specificities and sensitivities of the optimized assay and examined cross reactivity with immune sera from persons confirmed to have had infections with other coronaviruses. These assays will be used to perform contact investigations and to conduct large-scale, cross sectional surveillance to define disease burden in the population.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Performance estimation of two in-house ELISA assays for COVID-19 surveillance through the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulin isotypes 95%
- Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2 95%
- Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform 95%
Similar papers in this journal
Similar papers in this journal
- Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples 95%
- Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples 94%
- Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection 94%
Similar papers in this journal
- SARS-CoV-2 seroassay optimization and performance in a population with high background reactivity in Mali 97%
- Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco 94%
- SARS-CoV-2 Serosurveys: How antigen, isotype and threshold choices affect the outcome 94%
Similar papers in this journal
- Performance of three SARS-CoV-2 immunoassays, three rapid lateral flow tests and a novel bead-based affinity surrogate test for the detection of SARS-CoV-2 antibodies in human serum 96%
- Anti-SARS-CoV-2 antibody levels are concordant across multiple platforms but are not fully predictive of sterilizing immunity 95%
- A systematic evaluation of IgM and IgG antibody assay accuracy in diagnosing acute Zika Virus infection in Brazil; lessons relevant to emerging infections 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.